Burzynski Clinic Presents the Results of a Phase II Study of Antineoplastons in Adult Patients with Recurrent Glioblastoma Multiforme at the Congress

News provided by

Burzynski Clinic

26 Nov, 2013, 03:19 ET

HOUSTON, Nov. 26, 2013 /PRNewswire/ -- The Burzynski Clinic (BC) announced today that it has presented the results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent glioblastoma multiforme (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco.  GBM accounts for 60% of the primary brain tumors in adults and represents the most frequently occurring and the most malignant form of such tumors.  Treatment for recurrent GBM creates one of the most difficult challenges in neuro-oncology.  The study, presented at the poster session, accrued patients who developed disease progression during standard treatment within 8 weeks of completion of radiation therapy and 6 weeks from the completion of chemotherapy.  24 cases of recurrent GBM that progressed during prior standard treatment were eligible for evaluation.  ANP was administered intravenously for a median duration of 13 weeks.  Responses were assessed by magnetic resonance imaging (MRI).  Complete and partial responses were determined in 17% of cases.  Overall survival is 39% at 1 year and 4.4% at 2 years, 5 and 10 years.  The treatment was well-tolerated with reversible grades 3 and 4 toxicities including four cases of hypernatremia, two of fatigue, two of hyperkalemia, and a single case of somnolence.  There were no chronic toxicities.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws.  Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use personalized targeted cancer therapy.  Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

SOURCE Burzynski Clinic

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.